Gastrointestinal Cancer News

A trial designed to compare trifluridine and tipiracil with placebo for treatment of metastatic gastric cancer met its primary endpoint of OS, according to the agents’ manufacturer.

The phase 3 IMblaze370 trial evaluating atezolizumab in combination with cobimetinib did not meet its primary endpoint of OS compared with standard-of-care regorafenib for patients with locally advanced or metastatic colorectal cancer, according to the agents’ manufacturer.

Compliance with hepatocellular carcinoma surveillance correlated with early diagnosis, better allocation of curative treatment and longer overall survival among patients with hepatitis C- or hepatitis B-associated compensated cirrhosis, according to a recently published study.

The microbial population in the pancreas may provide information about the development of pancreatic cancer, according to research conducted at New York University.

Untreated patients with chronic hepatitis B in the immune-tolerant phase had higher risks for hepatocellular carcinoma, death or need for liver transplantation compared with patients in the immune-active phase treated with nucleos(t)ide analogues, according to recently published data.

The FDA granted fast track designations to 5F9 for the treatment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

Lymph node status following preoperative neoadjuvant therapy is a more important factor regarding survival rates than tumor status in patients with advanced esophageal cancer, according to research presented at the American Association for Thoracic Surgeons Annual Meeting in San Diego.

Screening rates for colorectal cancer varied significantly at the state and county level, according to a model-based study.

Stivarga therapy provided clinical benefit to patients with hepatocellular carcinoma and had similar adverse event rates regardless of the last Nexavar dose or time-to-progression on prior Nexavar therapy, according to a recently published study.

A pain-assessment tool with built-in treatment guidance reduced cancer-related pain outcomes, according to study data.